Answers are grounded in this paper and cite their sources.
Although ion channels represent ∼19% of human protein drug targets, and are the molecular targets for ∼18% of approved small-molecule drugs, rational design remains highly challenging. These membrane proteins cycle through multiple conformations and share highly conserved binding pockets. We review a decade of computational advances in ion channel drug design, presenting four case studies spanning from post-failure examination to prospective designs. We begin with TRPV1, where dose-limiting hyperthermia halted clinical trials. New structural data are starting to explain the difference between hyperthermia-causing vs. non-causing ligands. Next, we discuss hERG, an off-target case where cryo-EM and simulations revealed the structural basis of its promiscuity. This enabled drug discovery campaigns to proactively design out of this cardiac liability. We then examine Na V 1.8, where the recently approved suzetrigine proves that subtype selectivity is achievable despite high sequence conservation across sodium channels. Finally, for TRPM3, integrated cryo-EM, virtual screening, and medicinal chemistry yielded a picomolar antagonist, showcasing prospective drug design capability with computational structural biology. Together, these cases demonstrate how integration of cryo-EM, machine learning, and affinity calculations have transformed ion channel drug discovery. The field has evolved from using computational structural biology as a retrospective explanatory tool to a prospective design engine, accelerating design cycles.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: